Asthma: resource use and costs for inhaled corticosteroid vs leukotriene modifier treatment--a meta-analysis

J Fam Pract. 2003 May;52(5):382-9.


Objective: To compare the effects of inhaled corticosteroid treatment with leukotriene modifier treatment on medical resource use and costs for asthma patients.

Study design: Meta-analysis combining results from published and unpublished studies.

Data sources: Studies were identified from the MEDLINE and EMBASE databases and the GlaxoSmithKline internal database study registers. Two independent reviewers evaluated the identified studies; studies meeting specified inclusion criteria were abstracted and summarized by meta-analysis with a random effects model.

Outcomes measured: Hospitalization rate, emergency department visit rate, emergency department costs, drug costs, total asthma-related costs, and total medical care costs.

Results: Patients taking inhaled corticosteroids had: a significantly lower annual rate of hospitalization than those taking leukotriene modifiers (2.2% vs 4.3%, respectively; P<.05); a greater decline in hospitalization rate (before vs after therapy initiation) than those taking leukotriene modifiers (decline of 2.4% vs 0.55%; P<.01); a lower annual rate of emergency department visits than those taking leukotriene modifiers (6.2% vs 7.7%; P<.005); lower total asthma-related medical costs than those taking leukotriene modifiers (P<.05) and a 17% reduction in overall total medical care costs (P not significant).

Conclusions: Patients with asthma treated with inhaled corticosteroids have significantly fewer asthma-related hospitalizations and emergency department visits and lower total asthma-related health care costs than patients treated with leukotriene modifiers. These meta-analysis findings are consistent with results from randomized controlled trials showing improvements in lung function for patients taking inhaled corticosteroids as opposed to leukotriene modifiers.

Publication types

  • Comparative Study
  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Anti-Asthmatic Agents / administration & dosage
  • Anti-Asthmatic Agents / economics*
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / economics*
  • Asthma / drug therapy*
  • Drug Costs / statistics & numerical data
  • Emergency Service, Hospital / economics
  • Emergency Service, Hospital / statistics & numerical data
  • Health Care Costs / statistics & numerical data
  • Health Resources / economics
  • Health Resources / statistics & numerical data*
  • Health Services Research
  • Hospitalization / economics*
  • Humans
  • Leukotriene Antagonists / administration & dosage
  • Leukotriene Antagonists / economics*
  • Prospective Studies
  • Registries
  • Retrospective Studies
  • Steroids
  • Treatment Outcome
  • United Kingdom
  • United States


  • Anti-Asthmatic Agents
  • Anti-Inflammatory Agents
  • Leukotriene Antagonists
  • Steroids